Scientists have discovered a new potential therapy for malignant pancreatic cancer

Recently, scientists from Curtin University of science and technology in Australia have found a new potential therapy for the treatment of malignant pancreatic cancer, which is expected to increase the survival rate of patients who are resistant to current cancer chemotherapy drugs (http://www.chemdrug.com/) Relevant research is published in the International Journal of experimental & clinical cancer research In this paper, researchers found a special protein in human pancreatic duct adenocarcinoma cells (PDAC), which is very important for tumor progression The modified version of sulindac, an anti-inflammatory drug, may block the progression of cancer in the model of PDAC mice After using the PDAC mouse model, the researchers found that the modified sulindac could block the pathway of cancer progression or reduce the spread of PDAC and the growth of tumor in the body The results of this study are of great significance for the later human clinical trials (http://www.chemdrug.com/sell/24/); the special proteins found by the researchers will make cancer cells resistant to the currently available cancer chemotherapy drugs The overexpression of oncogenic proteins in cancers such as PDAC may be the reason why chemotherapy drugs can't effectively treat pancreatic cancer Targeting this protein may be able to effectively treat pancreatic cancer patients who can't be effectively treated by standard therapy, the researchers said Further studies are needed to determine whether a specific combination of drugs (including modified versions of sulindac) can achieve the desired results in clinical trials; if successful, the new therapy may increase the survival rate of patients with pancreatic cancer Modified sulindac can reduce the side effects of anti-inflammatory drugs Finally, the modified sulindac may be effective in the treatment of patients with PDAC, and the researchers will develop a new targeted drug therapy based on the results of this study to treat malignant metastatic pancreatic cancer.